Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00231166 |
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: HCD122 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Dose-Finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Novartis | 862 778 8300 |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
St. Vincent's Comprehensive Cancer Center | Recruiting |
New York, New York, United States, 10011 | |
United States, Pennsylvania | |
University of Pennsylvania Abramson Cancer Center | Recruiting |
Philadelphia, Pennsylvania, United States, 19014 | |
United States, Washington | |
Fred Hutchinson Cancer Research Center | Recruiting |
Seattle, Washington, United States, 98109 | |
Australia | |
Recruiting | |
Brisbane, Australia | |
Recruiting | |
Melbourne, Australia | |
Recruiting | |
Adelaide, Australia | |
Recruiting | |
Canberra, Australia |
Study Chair: | Novartis | Novartis |
Study ID Numbers: | CHCD122A2102 |
Study First Received: | September 30, 2005 |
Last Updated: | January 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00231166 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Immunoproliferative Disorders Immunologic Factors Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases Paraproteinemias Hemostatic Disorders |
Multiple Myeloma Antibodies, Monoclonal Signs and Symptoms Antibodies Hemorrhagic Disorders Lymphoproliferative Disorders Immunoglobulins Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Immunoproliferative Disorders Immunologic Factors Immune System Diseases Blood Protein Disorders Hematologic Diseases Physiological Effects of Drugs Vascular Diseases Paraproteinemias |
Hemostatic Disorders Pharmacologic Actions Multiple Myeloma Antibodies, Monoclonal Neoplasms Hemorrhagic Disorders Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |